pemetrexed /carboplatin

DRUG2 trials

Sponsors

Fudan University, Shenyang Sunshine Pharmaceutical Co., LTD.

Conditions

First-line Advanced NSCLC PatientsNon-small Cell Lung Cancer

Phase 2

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients

RecruitingNCT07171606

Shenyang Sunshine Pharmaceutical Co., LTD.First-line Advanced NSCLC Patients

Start: 2025-10-24End: 2027-08-31Target: 240Updated: 2025-12-18

Unknown Phase

A Study of PC Sequential Pemetrexed Single Drug Maintenance Treatment for NSCLC and Related Predictive Biomarkers

Fudan UniversityNon-small Cell Lung Cancer

Start: 2013-02-28Target: 94Updated: 2013-07-08

Related Papers

Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer

Oncotarget2017-09-237 citations